2010-09-29

PRESS RELEASE

Communiqué from Annual General Meeting

Oasmia Pharmaceutical AB (publ.) VAT no SE556332-667601 held its AGM on Tuesday, September 28, 2010 for the fiscal year 2009/2010 where the following resolutions were made. For more detailed information about the content of the resolutions, see the complete notice for the AGM which is available at the Oasmia Pharmaceutical website www.oasmia.com together with the complete proposals for the resolutions below.

Establishment of Balance Sheet and Income Statement
The AGM established the Balance Sheet, Income Statement, Consolidated Accounts and Financial report. It was resolved that the accumulated loss of SEK -44 628 446, loss for the year SEK -18 401 081 and share premium reserve SEK 196 493 091 shall be carried forward.

The Board of Directors
The AGM discharged the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2009/2010. The Meeting made a resolution that the Board shall consist of five regular members without deputies. The AGM re-elected the Board members Bo Cederstrand, Peter Ström, Claes Piehl and Julian Aleksov and newly elected Björn Björnsson. Bo Cederstrand was re-elected as chairman of the Board.

Remuneration to the Board and auditors
The AGM established that a member of the Board who is not employed by the company shall receive remuneration amounting to SEK 25 000 per attended meeting. Remuneration to a Board member may, by special agreement with Oasmia Pharmaceutical AB, be invoiced by a company wholly-owned by the Board member. In that case, the invoiced fee is increased by the amount of social security contributions and VAT. Remuneration to the auditors shall be paid according to bill.

Guidelines for remuneration to senior managers
The AGM approved the by the Board proposed guidelines for remuneration to senior managers.

Nomination committee
The AGM approved the proposal concerning criteria for the selection of a nomination committee for the AGM 2011.

For more information, please contact: Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. Information is also available at nasdaqomxnordic.com and oasmia.com

Authorization for the Board to make decisions of issue of new shares and convertible debt instruments

The AGM made a resolution to, in accordance with the proposal by the Board, authorize the Board to make, at one or more occasions, with or without deviation from shareholders' preferential rights, new share issues for cash payment and/or in kind or offset, or otherwise in accordance with chap 13 § 7 of the Companies Act. The total number of shares issued supported by the authorization may not exceed 15 000 000. The total number of convertibles issued supported by the authorization may not exceed more convertibles than enables conversion to 15 000 000 shares.